Τόμος 23 (2009) – Τεύχος 3 – Άρθρο 11 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 23 (2009) – Issue 3 – Article 11 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Title Technetium 99m, as a tracer in nuclear medicine procedures
Authors Athanasios Zisimopoulos1, Grigorios Kyriatzis2, Fotoula Babatsikou3, Dimitrios Psyllas1, Evangelos Karathanos1 and Charilaos Koutis4

1.      Department of Nuclear Medicine, University General Hospital of Alexandroupolis Medical School, Democritus University, Alexandroupolis, Hellas

2.     Unit of Molecular biology, Democritus University, Molecular Biology and Genetics, Alexandroupolis,Hellas

3.     Department of Nursing, Technological Educational Institution of Athens (TEI), Athens, Hellas

4.     Laboratory of Epidemiology, Technological Educational Institution of Athens (TEI), Athens, Hellas

Citation Zisimopoulos, A., Kyriatzis, G., Babatsikou, F., Psyllas, D., Karathanos, E. et al.: Technetium 99m, as a tracer in nuclear medicine procedures, Epitheorese Klin. Farmakol. Farmakokinet. 23(3): 171-176 (2009)
Publication Date Accepted for publication (Final Version): July 1, 2009
Full Text Language English
Order – Buy  Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €) 

pharmakonpress[at]pharmakonpress[.]gr

Keywords Technetium 99m, tracer, pharmacokinetics, nuclear medicine.
Other Terms review article
Summary Technetium 99m is a metastable artificial radioisotope used as a radiotracer with advanced and plenty applications in Nuclear Medicine. It is the decay product (daughter element) of Mo-99 following beta decay with half life of 6.03 hours in its metastable state. It has properly physical and chemical characteristics and thus plays a lead role in radiopharmaceutical industry. Under appropriate conditions such as oxidation number, pH, hydrophilic characteristics can produce multiple stable complexes applicative to participate in almost any physical or metabolic pathways to identify a disease or pathological conditions.
References 1. Webb S.: The physics of medical imaging. Printed by ‘IOP Publishing Ltd’ Institute of Publishing, Bristol and Philadelphia, 1998

2. Douglas J. Simpkin: Radiation Interaction and Internal Dosimetry. Department of Radiology, St Luke’s Medical Center, 2900 W Oklahoma Ave, Milwaukee, WI 53149, 1997

3. Kandarakis I.: Physical and chemical principles of Nuclear Medicine. Printed by ‘ELLIN’ 4th edition, 2006

4. Harbert J., Rocha A.: Textbook of Nuclear Medicine. Vol.1, Second edition. Lea and Febiger, Philadelphia, 1984

5. Pizarrello D.J., Witcofski R.L.: Medical Radiation Biology. Lea and Febiger, Philadelphia, 1984

6. Technetium 99m (99mTc): Division of Environmental Health, Office of Radiation Protection: Washington State Department of Health – Office of Radiation and Health, Washington DC, July 2002

7. MedPhysics, Inc., Amersham Healthcare. Product Information Issued, May 1997

8. Garet R.: Bone destruction in cancer. Semin. Oncol. 20(Suppl. 2): 4-9 (1993)

9. Zissimopoulos A.: Clinical application of Nuclear Medicine. Medical publications P.X. Paschalidis, Athens, 2004

10. Woodle E.S., Vera D.R., Stadalnik R.C., Ward R.E.: Tc-NGA imaging in liver transplantation: preclinical studies. Surgery 102: 55-62 (1987)

11. Kim J.S., Kim J. I., Bae T.Y., Kim K.Y., Kim S. D.: Comparison of early and delayed quantified indices of doublephase (99m)Tc MIBI scintimammography in the detection of primary breast cancer. Acta Radiol. 46: 148-154 (2005)

12. Kung M.P., Stevenson D.A., Plössl K., Meegallas S.K., Beckwith A., Essman W.D., MU M., Lucki I, Kung H.F.: 99mTc-TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur. J. Nucl. Med. 24: 373-380 (1997)

Relative Papers

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:

Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor

Τι είναι η Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς – 
What is Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – 
Articles Published in Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2009 – ANNUAL SUBSCRIPTION 2009
Γλώσσα Πλήρους Κειμένου – Full Text Language Αγγλικά – English
Παραγγελία – Αγορά – Order – Buy Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)

pharmakonpress[at]pharmakonpress[.]gr

Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)

pharmakonpress[at]pharmakonpress[.]gr

 

 

Bookmark the permalink.

Comments are closed.